Seaport Therapeutics, Inc.
No SEC Form 4 filings for $SPTX in the last 30 days.
See all $SPTX insider activity →Seaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM in major depressive disorder (MDD) is on track with
HOMBACH ROBERT J. purchased 13,000 indirectly-held shares of Seaport Therapeutics, Inc. (SPTX) at $18.14 ($0.24M total) on 2026-06-22.
PureTech’s founded entity Seaport Therapeutics reported positive Phase 1 multiple-ascending dose data for GlyphAgo (SPT-320) in healthy volunteers. Seaport said seven-day repeat dosing showed favorable safety/tolerability and PK consistent with prior single-dose results, with no liver-related adverse events and dose-dependent agomelatine exposure. Seaport plans Phase 2a in H2 2026 (topline early 2028) and Phase 2b in H1 2027 (topline by end-2028).
Over the past 7 days, alphai's AI scored 1 news story mentioning SPTX (Seaport Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SPTX coverage spans earnings, insider activity and technology.
Clinical and funding runway updates increase visibility into near-term catalysts for SPTX’s lead programs, especially GlyphAllo BUOY-1 topline timing and GlyphAgo advancement.
Routine insider buying disclosure; may modestly support sentiment but is not a fundamental catalyst by itself.
Positive MAD data de-risks dose selection and supports advancement into two Phase 2 trials for GAD, with a liver-safety/monitoring differentiation versus agomelatine.
Clinical de-risking (GlyphAgo liver-safety exposure profile) and enrollment/financing runway into 2029 support a constructive risk/reward, with near-term catalysts tied to 2H 2026 and 1H 2027/early 2028 readouts.
alphai scores every news story that mentions SPTX with an AI model for sentiment and relevance, and aggregates insider trades from Seaport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Seaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM in major depressive disorder (MDD) is on track with
6 min readHOMBACH ROBERT J. purchased 13,000 indirectly-held shares of Seaport Therapeutics, Inc. (SPTX) at $18.14 ($0.24M total) on 2026-06-22.
2 min readPureTech’s founded entity Seaport Therapeutics reported positive Phase 1 multiple-ascending dose data for GlyphAgo (SPT-320) in healthy volunteers. Seaport said seven-day repeat dosing showed favorable safety/tolerability and PK consistent with prior single-dose results, with no liver-related adverse events and dose-dependent agomelatine exposure. Seaport plans Phase 2a in H2 2026 (topline early 2028) and Phase 2b in H1 2027 (topline by end-2028).
6 min readSeaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress New data from Phase 1 trial of GlyphAgo TM build upon previously reported topline data and further demons
6 min read
